GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CVRx Inc (NAS:CVRX) » Definitions » Accumulated other comprehensive income (loss)

CVRx (CVRX) Accumulated other comprehensive income (loss) : $-0.21 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CVRx Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. CVRx's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2024 was $-0.21 Mil.

CVRx's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2023 ($-0.21 Mil) to Dec. 2023 ($-0.21 Mil) but then declined from Dec. 2023 ($-0.21 Mil) to Mar. 2024 ($-0.21 Mil).

CVRx's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 ($-0.20 Mil) to Dec. 2022 ($-0.21 Mil) but then stayed the same from Dec. 2022 ($-0.21 Mil) to Dec. 2023 ($-0.21 Mil).

CVRx Accumulated other comprehensive income (loss) Historical Data

The historical data trend for CVRx's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CVRx Accumulated other comprehensive income (loss) Chart

CVRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
-0.19 -0.19 -0.20 -0.21 -0.21

CVRx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.20 -0.19 -0.21 -0.21 -0.21

CVRx Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

CVRx Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of CVRx's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

CVRx (CVRX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CVRx Inc (NAS:CVRX) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
NNOX SILK TCMD SENS CERS RCEL ARAY BVS LUNG ALUR ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
9201 West Broadway Avenue, Suite 650, Minneapolis, MN, USA, 55445
Website
https://www.cvrx.com
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Executives
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Paul Verrastro officer: Chief Marketing Officer 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Kevin Hykes director 2 GOODYEAR, SUITE B, IRVINE CA 92618
Kirk G. Nielsen director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Mudit K. Jain director C/O TREO VENTURES, 140 WASHINGTON STREET, SUITE 200, RENO NV 89503
Craig E. Palmer officer: SVP, U.S. Sales 9201 WEST BROADWAY AVENUE, SUITE 650, MINNEAPOLIS MN 55445
Martha Shadan director 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
New Enterprise Associates 10 L P 10 percent owner
Nea Partners 10 L P 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Geoffrey B Pardo director 100 DOMAIN DRIVE, EXETER NH 03833
Jared Oasheim officer: Chief Financial Officer 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
John Brintnall officer: Chief Strategy Officer and Sec 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Dean Bruhn-ding officer: VP of Reg. Affairs and QA 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Liz Galle officer: VP of Global Clinical Research 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Nadim Yared director, officer: Chief Executive Officer 9201 W BROADWAY AVE #650, MINNEAPOLIS MN 55445